Research programme: interferon beta - HanAll Biopharma

Drug Profile

Research programme: interferon beta - HanAll Biopharma

Alternative Names: HL144; Interferon-beta - HanAll Biopharma

Latest Information Update: 11 Mar 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nautilus Biotech
  • Developer HanAll Biopharma
  • Class Interferons
  • Mechanism of Action Interferon beta stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Multiple sclerosis

Most Recent Events

  • 11 Mar 2011 No development reported - Preclinical for Multiple sclerosis in South Korea (SC)
  • 21 Sep 2010 Research programme: interferon beta - HanAll Pharmaceutical is available for licensing (www.hanallbiopharma.com)
  • 20 Jul 2004 This programme is available for licensing (http://www.nautilusbiotech.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top